ADRO stock news

Aduro Biotech (ADRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics Inc (NASDAQ: ANIK )( reported better-than-expected second-quarter results) Novocure Ltd (NASDAQ: NVCR )(reported strong second-quarter results) Repligen Corporation (NASDAQ: RGEN ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Baxter International Inc (NYSE: BAX ) (reacted to strong second-quarter results) West Pharmaceutical Services Inc. (NYSE: WST ) (reacted to strong second-quarter results) Myovant Sciences Ltd (NYSE: MYOV ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 25) Abeona Therapeutics Inc (NASDAQ: ABEO )(announced results from a Phase 1/2 trial of its ABO-102, its gene therapy candidate for San Filippo syndrome Type A) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP )(announced initiation of trial dubbed SPEARHEAD-1 that is evaluating ADP-A2M4 SPEAR T cells for patients with synovial sarcoma or myxoid/round cell liposarcoma) Aduro BioTech Inc (NASDAQ: ADRO ) Alkermes Plc (NASDAQ: ALKS )(reacted to Q2 results) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Assembly Biosciences Inc (NASDAQ: ASMB ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) ChemoCentryx Inc (NASDAQ: CCXI ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Innoviva Inc (NASDAQ: INVA )(reported below-consensus second-quarter results) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Neon Therapeutics Inc (NASDAQ: … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH )(announced a deal to buy University of Minnesota startup B-MoGen technology) Blueprint Medicines Corp (NASDAQ: BPMC ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 6) Acorda Therapeutics Inc (NASDAQ: ACOR ) Aduro BioTech Inc (NASDAQ: ADRO ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptinyx Inc (NASDAQ: APTX ) Axovant Gene Therapies Ltd (NASDAQ: AXGT )(reported six-month follow-up data from the first dose cohort in the Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease and also issued pipeline update) Bellicum Pharmaceuticals (NASDAQ: BLCM ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Cellectis SA (NASDAQ: CLLS ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evolent Health Inc (NYSE: EVH ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Hemispherx BioPharma, Inc (NYSE: HEB ) IMMURON LTD/S ADR (NASDAQ: IMRN ) IMMUTEP LTD/S ADR (NASDAQ: IMMP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) Neuronetics Inc (NASDAQ: STIM ) Puma Biotechnology Inc (NASDAQ: PBYI ) Seres Therapeutics Inc (NASDAQ: … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd … Read more
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding week is all about the presentations at one of the largest educational and scientific events for the oncology community. Here are the key events/catalysts to look forward to: Conferences The American Society of Clinical Oncology, or ASCO, 2019 Annual Meeting – May 31–June 4, in Chicago, Illinois The European Academy of Allergy and Clinical Immunology 2019 Annual Congress – June 1-5, in Lisbon, Portugal 20th Global Nephrologists Annual Meeting - June 3-4, in London Jefferies 2019 Healthcare Conference – June 4-7, in New York City European Society for Pediatric Gastroenterology, Hepatology and Nutrition 2019 Annual Meeting – June 5-8, in Glasgow, Scotland HBV Cure Meeting – June 7-8, in Singapore The American Diabetes Association's 79th Scientific Sessions – June 7-11, in San Francisco, California PDUFA Dates The FDA is scheduled to rule Monday on Merck & Co., Inc. (NYSE: MRK )'s sNDA for Zerbaxa (ceftolozone and tazobactam) in treating adult patients with ventilated nosocomial (hospital-acquired) pneumonia ASCO Presentations On Sunday, June 2 Aduro BioTech Inc (NASDAQ: ADRO ) – Phase 1b data for ADU-S100 and Spartalozumab (solid tumors or lymphomas) Celgene Corporation (NASDAQ: CELG ) – Phase 1/2 data on CC-220 (relapsed and/or refractory multiple myeloma) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) – already-released Phase 2 data for Namodenoson (second-line treatment of advanced liver cancer) Amgen, Inc. (NASDAQ: AMGN ) – Phase 1 data for AMG 420 (relapsed, refractory multiple myeloma) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) – Phase 1 data for Ad-RTS-Hil-12 (recurrent glioblastoma) as well as initial Phase … Read more
Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences Read more
Aduro Biotech (ADRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more

Aduro Biotech (ADRO) Signal & Momentum Update

06:50am, Tuesday, 02'nd Apr 2019
Interested investors might be taking a look at the medium range signals for Aduro Biotech (ADRO). The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is mainly use Read more
Analysts expect Aduro BioTech, Inc. (NASDAQ:ADRO) to report $-0.22 EPS on May, 1.They anticipate $0.06 EPS change or 21.43 % from last quarter's $-0.28 EPS. Read more
Traders and investors may be taking note of Aduro Biotech (ADRO) shares and how they are expected to move mid-term. The reading from the 40-day commodity channel index is currently Hold. The CCI indic Read more
This is a contrast between Aduro BioTech Inc. (NASDAQ:ADRO) and ArQule Inc. (NASDAQ:ARQL) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional Read more
As Biotechnology businesses, Aduro BioTech Inc. (NASDAQ:ADRO) and Five Prime Therapeutics Inc. (NASDAQ:FPRX), are affected by compare. This especially applies to their dividends, analyst recommendatio Read more

Proudly made at

ROCKIT